NCT06979531View on ClinicalTrials.gov

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Primary Sjögren's Syndrome
Interventions
DRUG

IMVT-1402

Administered once weekly by subcutaneous injection

DRUG

Placebo

Administered once weekly by subcutaneous injection

Trial Locations (3)

33321

RECRUITING

Site Number - 1004, Tamarac

38119

RECRUITING

Site Number - 1000, Memphis

75013

RECRUITING

Site Number - 1001, Allen

Sponsors
All Listed Sponsors
lead

Immunovant Sciences GmbH

INDUSTRY

NCT06979531 - Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity | Biotech Hunter | Biotech Hunter